| First Author | Withers DR | Year | 2016 |
| Journal | Nat Med | Volume | 22 |
| Issue | 3 | Pages | 319-23 |
| PubMed ID | 26878233 | Mgi Jnum | J:233321 |
| Mgi Id | MGI:5781257 | Doi | 10.1038/nm.4046 |
| Citation | Withers DR, et al. (2016) Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med 22(3):319-23 |
| abstractText | RAR-related orphan receptor-gammat (ROR-gammat) directs differentiation of proinflammatory T helper 17 (TH17) cells and is a potential therapeutic target in chronic autoimmune and inflammatory diseases. However, ROR-gammat-dependent group 3 innate lymphoid cells ILC3s provide essential immunity and tissue protection in the intestine, suggesting that targeting ROR-gammat could also result in impaired host defense after infection or enhanced tissue damage. Here, we demonstrate that transient chemical inhibition of ROR-gammat in mice selectively reduces cytokine production from TH17 but not ILCs in the context of intestinal infection with Citrobacter rodentium, resulting in preserved innate immunity. Temporal deletion of Rorc (encoding ROR-gammat) in mature ILCs also did not impair cytokine response in the steady state or during infection. Finally, pharmacologic inhibition of ROR-gammat provided therapeutic benefit in mouse models of intestinal inflammation and reduced the frequency of TH17 cells but not ILCs isolated from primary intestinal samples of individuals with inflammatory bowel disease (IBD). Collectively, these results reveal differential requirements for ROR-gammat in the maintenance of TH17 cell and ILC3 responses and suggest that transient inhibition of ROR-gammat is a safe and effective therapeutic approach during intestinal inflammation. |
